Insilico Medicine, Inc. is utilizing a machine learning technique called deep learning for drug repurposing research. This new process will be part of their DeepPharma (TM) platform. The technique borrows some of its principles from the brain and gives computers the ability to recognize speech and categorize images–given these advances, it will be able to greatly accelerate research. Next month, the company plans to hire more data scientists at their first-ever deep learning “neuro hackathon”. The event will spark involvement in working to transform the pharmaceutical industry. Insilico is known for focusing on cancer and other age-related diseases in their research.
For more on Insilico, click here.